Antibodies are among the most widely used tools in modern biology. These Y-shaped proteins, exploited for their remarkable ability to recognize specific molecular shapes, allow researchers to detect, quantify, and isolate particular proteins within complex biological samples. Techniques ranging from Western blotting and immunohistochemistry to flow cytometry and diagnostic assays all depend on antibodies binding precisely to their intended targets. Yet the reagents sold for these purposes do not always behave as their suppliers claim. Research antibodies can fail to bind their intended targets, or they can bind additional, unintended targets, producing signals that look convincing but reflect nothing more than molecular coincidence. Studies have suggested that many commercial antibodies simply do not bind as advertised, and this lack of specificity can quietly misdirect biomedical research across virtually every field that touches proteins.

The first of the two studies, led by Virk with first author Michael Biddle, set out to measure the consequences of that failure rather than merely describe it. The team combined three strands of evidence: focus groups involving 12 researchers, a survey of 107 researchers, and an analysis of 785 publications linked to antibodies that had failed rigorous, knockout-controlled testing. Knockout validation, in which the target protein is genetically removed to confirm that the antibody’s signal disappears along with it, is considered one of the most stringent checks available, so antibodies failing such tests provide a well-grounded proxy for reagents that cannot be trusted.

The results of that analysis were sobering. Among 760 publications in which the validation status of the antibodies could be determined, only 120, or 15.8 percent, presented any validation evidence at all. This shortfall was not explained by researchers being unaware of good practice. In the survey, 72.0 percent of respondents reported having used at least one recommended validation method, a striking disconnect between what scientists say they do and what the published record shows. The papers lacking antibody validation had used a minimum of 8,064 animal samples and 4,424 human tissue samples, and when the team extrapolated from these figures, they estimated that millions of animal and human tissue samples have been consumed globally in experiments resting on inadequately validated antibodies.

“This study provides, to our knowledge, the first systematic quantification of biological sample waste attributable to the use of poorly performing antibodies without context-specific validation,” the researchers say. Biddle emphasized the scale of the problem in the starkest terms. Researchers told the team they validate their antibodies, he noted, with 72 percent reporting use of at least one recommended method, yet only 120 of the 760 papers the team could assess showed any validation evidence. The remaining 640 studies reported at least 8,064 animal and 4,424 human tissue samples used with antibodies that had failed independent testing, samples the authors describe as being at risk of waste. In the clearest cases, where the antibody has since been withdrawn from sale so that the work cannot be reproduced at all, scaling to the commercial antibody market yields a lower-bound global estimate of 4 to 7 million animal samples and 6 to 11 million human tissue samples.

Behind the numbers lies a human and ethical dimension that Virk knows personally. “Around ten years ago I discovered that data I had submitted in a grant application relied on an antibody that did not detect its intended target,” he says. “The data included staining of bronchial biopsies from patients who had given informed consent. They would not have expected their donation to be wasted. That has driven this work ever since.” That experience, a trusted reagent failing silently and rendering a patient’s contribution scientifically useless, crystallized the problem the two studies now document at scale: every unvalidated antibody is not merely a technical risk but a potential squandering of animals sacrificed, patients’ tissues donated, and public research funding spent.

Quantifying the damage was only half of the project. In the second study, Virk and first author Katherine Blades convened 32 international experts, including researchers, publishers, funders, antibody manufacturers, and institutional leaders, for a two-round Delphi consensus exercise. The Delphi method, a structured process in which participants anonymously rate and re-rate proposals across successive rounds, is designed to surface genuine agreement while filtering out the noise of group dynamics. The panel was asked to judge proposed reforms for antibody validation on two axes: whether each action would be effective, and whether it would be feasible to implement.

The consensus that emerged was remarkably concrete. The panel agreed that 15 actions, including institutional training programs, dedicated validation budgets written into grant applications, and publisher reporting requirements, were both effective and feasible for implementation by 2030. A further 15 actions were judged effective but of uncertain feasibility, marking out a second tier of reforms that could follow once the groundwork is laid. Participants identified two key barriers standing in the way: the diffuse ownership of the problem, with no single stakeholder clearly responsible for fixing it, and market incentives that fail to reward antibody quality, allowing poorly performing products to compete on price rather than performance.

“What struck us was the level of agreement once researchers, funders, publishers, institutions and manufacturers were brought into the same process,” Blades says. “The panel reached consensus on 15 actions that are both effective and achievable by 2030. Progress is held back not by disagreement about what to do, but because no single group owns the problem — so everyone waits for someone else to move first.” To translate that consensus into practice, the team has prepared separate documents for each stakeholder group, presenting the agreed recommendations alongside implementation options drawn from the panel’s qualitative feedback. These documents deliberately present options rather than prescriptions, recognizing that the optimal approach will vary across organizations, countries, and contexts.

The work is already moving from analysis to action. Since completing the studies, the team has embedded champions for better antibody practice in 14 UK research institutions, and the University of Leicester has made antibody validation training mandatory for its bioscience postgraduate researchers. The researchers are working with two national funders, the NC3Rs and Cancer Research UK, on implementation solutions, and they have built free tools that publishers can use to protect the integrity of what they publish. “Together these papers show the problem has significant impact with ethical dimensions, and is solvable,” Virk says. The message to the research community is unusually hopeful for a field accustomed to reproducibility crises: the waste is enormous, the causes are identifiable, and, for the first time, a broad coalition of stakeholders has agreed on a concrete, dated path to fixing it.

Subject of Research: Antibody validation failures and biological sample waste in biomedical research

Article Title: Poor antibody validation wastes millions of biological samples, but solutions exist

Article References: Poor antibody validation wastes millions of biological samples, but solutions exist. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: antibody validation, research reproducibility, PLOS Biology, biological sample waste, animal research, Delphi consensus, research integrity, knockout validation, University of Leicester, publishing standards, research funding, biomedical reagents

Early onset type 2 diabetes, abbreviated EOT2D, is increasingly recognised by clinicians as a distinct and particularly aggressive clinical phenotype. Because it strikes in the third and fourth decades of life, the disease has decades longer to inflict damage on blood vessels, nerves, kidneys and the heart. People diagnosed young experience more rapid deterioration in blood sugar control, develop complications earlier, and face a lower life expectancy than those whose type 2 diabetes appears later in life. As rates of obesity rise across the globe, the number of young adults affected is climbing steeply, making the search for potent, disease-modifying interventions an urgent priority for health systems worldwide.

The biological rationale behind the trial, known as RESET for Remission, rests on the complementary effects of dietary energy restriction and exercise. Low energy diets have previously been shown to drive glucose levels below the diagnostic threshold for type 2 diabetes without the need for medication, a state defined as remission. Adding structured exercise may deliver synergistic advantages: greater cardiorespiratory fitness, preservation of muscle mass during rapid weight loss, enhanced cardiac function, and reduced insulin resistance. The researchers reasoned that a condition as aggressive as early onset type 2 diabetes merits an intervention powerful enough to arrest its swift evolution, and they designed the study to test whether combining the two approaches would outperform usual care.

The trial was a randomised, open-label, blinded endpoint efficacy study conducted across three centres in England and Canada, affiliated with the University of Leicester, McGill University in Montreal, and the University of Alberta in Edmonton. It enrolled adults aged 18 to 45 with early onset type 2 diabetes and obesity who were not taking insulin therapy. Between September 24, 2021 and June 6, 2025, a total of 96 participants were randomised, 40 in the United Kingdom and 56 in Canada. The intervention group comprised 24 women and 26 men, while the control group had 21 women and 25 men. The mean age of participants was 38 years and the mean body mass index was 35.2 kilograms per square metre. Notably, 86 participants, or 90 percent, attended final assessments, a retention rate that strengthens confidence in the findings.

The intervention itself was demanding but carefully structured. Participants stopped all glucose-lowering and blood pressure-lowering medication, in the absence of albuminuria, as they began an 800 to 900 kilocalorie per day diet providing 30 percent of energy from protein, 50 percent from carbohydrate and 20 percent from fat. They were encouraged to drink at least two litres of calorie-free fluid daily and were given a fibre-based laxative to use as required. The first two weeks consisted of total meal replacement using Optifast. From weeks 3 to 12, the same caloric intake continued with more variety, using Optifast in the United Kingdom and ProtiDiet in Canada, alongside one food-based meal per day supplying 60 to 90 grams of protein from all sources combined, one portion of fruit and two portions of non-starchy vegetables.

Exercise ran in parallel with the dietary phase. During weeks 1 to 12, participants completed twice-weekly supervised sessions covering both aerobic and resistance training, plus one weekly independent exercise session. From weeks 13 to 24, they transitioned to a weight-maintenance diet while continuing independent exercise. The primary outcome was remission at 24 weeks, defined as a glycated haemoglobin level below 6.5 percent, or 48 millimoles per mole, together with the absence of glucose-lowering medication for at least 12 weeks. The primary efficacy and harms analysis included all randomised individuals, with a conservative assumption that missing data meant no remission. Secondary endpoints captured cardiorespiratory fitness, body composition and cardiac structure.

The results were striking across multiple dimensions. Intervention participants, who averaged 100.7 kilograms at baseline, lost a mean of 8.4 kilograms by week 24, reaching an average weight of 92.3 kilograms. Control participants, who averaged 103.2 kilograms at the start, lost only 1.2 kilograms, ending at a mean of 102.0 kilograms. After statistical adjustment, the analysis showed that intervention participants lost 7.5 kilograms more than controls, including 6.6 additional kilograms of fat mass. Critically, the trial demonstrated that fat-free mass and muscle preservation are achievable even during rapid weight loss, a finding the authors attribute to the resistance training component that deliberately targeted muscle during the intensive dietary phase.

Safety data were reassuring. Remission was achieved without any severe adverse events. Most participants in the intervention group, 43 of 50, experienced at least one adverse event, compared with 6 of 46 in the control group, but these were mainly the familiar early effects of very low energy diets, such as constipation, headache, dizziness and fatigue, all of which resolved. This profile mirrors what has been reported in previous meal replacement trials and suggests that, under appropriate supervision, the intervention is tolerable for the majority of young adults willing to undertake it.

The authors emphasised the breadth of the benefits beyond blood sugar control. In their summary of the RESET for Remission findings, they report that combining structured aerobic and resistance exercise with a low-calorie diet produced high remission rates, induced fat loss while preserving muscle mass, improved muscle quality and function, enhanced cardiovascular health, and led to meaningful improvements in patient-reported outcomes. They noted that their remission rates sit at the upper end of those previously reported in the literature for trials of similar duration, and that this is the first time such effects have been demonstrated in a multi-ethnic population with early onset type 2 diabetes through a combined low energy diet and structured exercise intervention.

The researchers are candid about the challenges that remain. All weight loss programmes, including low energy diets used for type 2 diabetes remission, are typically followed by a period of partial or full weight regain for most people. Because weight loss driven by lower energy intake alone reduces both fat and fat-free mass, and there is some evidence that weight regain may preferentially restore fat over fat-free mass, there is a long-term risk of net muscle loss and increased sarcopenia. Preserving muscle during remission-oriented weight loss, they argue, may have important implications for long-term metabolic health, physical function and disease trajectory, though this requires confirmation in longer-term studies. They also highlight that their approach may be particularly valuable for those seeking or with potential for pregnancy, a group in which medication options are limited. As the global prevalence of early onset type 2 diabetes continues to rise, the team concludes that the findings present an opportunity to re-evaluate treatment paradigms and support scalable implementation of integrated dietary and exercise interventions, pending further evaluation in real-world settings.

Subject of Research: Remission of early onset type 2 diabetes through a combined low energy diet and structured exercise intervention

Article Title: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants

Article References: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 2 diabetes, diabetes remission, low energy diet, structured exercise, early onset diabetes, randomised controlled trial, weight loss, resistance training, McGill University, University of Leicester, EASD, The Lancet Regional Health Americas

The research team examined 2,756,553 net finishing times from marathons held in Berlin, Boston, Chicago, London, New York City and Tokyo between 2010 and 2024. By combining this vast performance dataset with race-day measurements of air pollutants at each event, the researchers were able to test whether short-term exposure to urban air pollution left a measurable imprint on human endurance. The study, led by Dr James Donaldson, Postdoctoral Researcher in Health and the Environment at the University of Leicester, and involving investigators including Professor Andre Ng, Dr Samuel Cai and Professor Anna Hansell, was published in Sports Medicine Open in September 2026 and was supported by the National Institute for Health and Care Research Biomedical Research Centre Leicester.

The headline finding concerns nitrogen dioxide, a pollutant generated mainly by road traffic and combustion processes. According to Dr Donaldson, each additional microgram per cubic metre of nitrogen dioxide was associated with a finishing time 1.43 minutes slower in men and 1.56 minutes slower in women. In the context of a marathon, where elite competitors are separated by seconds and where personal bests are often chased for years, a slowdown of more than a minute per microgram per cubic metre represents a substantial effect, particularly given that pollution levels across the studied races were generally only low to moderate by global standards.

The pattern of vulnerability within the field of runners was striking. The negative effects of nitrogen dioxide were approximately six times larger for recreational runners than for elite athletes, and younger runners aged 18 to 29 showed larger effects than older participants. This gradient suggests that the performance cost of polluted air is not distributed evenly across the field, but instead concentrates among the mass of amateur runners who make up the overwhelming majority of participants in the World Marathon Majors and who often spend four, five or more hours on the course.

Dr Donaldson offered several potential explanations for these patterns. Slower runners remain on the marathon course for longer, meaning they accumulate a greater dose of pollutants over the duration of the race. In addition, the physiological adaptations produced by the high-intensity training undertaken by elite athletes may confer some protection against the harmful effects of air pollution on performance. Recreational runners, who typically have less training behind them, may find that the added physiological strain imposed by pollution during a marathon has a comparatively greater effect on their result.

Notably, the study did not find a statistically significant relationship between fine particulate matter, known as PM2.5, and marathon finishing times. Fine particulate matter consists of tiny airborne particles generated by vehicle emissions, industry, heating and other combustion-related sources, and both nitrogen dioxide and particulate pollution have been linked to adverse health effects, particularly on the heart and lungs. The absence of a significant particulate-matter signal in this dataset may reflect the relatively low and narrow range of PM2.5 concentrations observed on race days, which limits the ability of statistical models to detect an effect even if one exists at higher exposures.

An important contextual point is that race-day concentrations of nitrogen dioxide and PM2.5 in this sample were generally low to moderate relative to the 2021 World Health Organization air quality guideline levels, with most of the marathons falling near or below those thresholds. That effects of this size emerged at such modest concentrations carries implications well beyond elite sport. It suggests that even air quality considered acceptable by international standards may measurably constrain human physical performance during prolonged maximal exertion, when ventilation rates rise dramatically and large volumes of air are drawn deep into the lungs.

Professor Bryan Williams, Chief Scientific and Medical Officer at the British Heart Foundation, which supported the study, cautioned that the research is observational and cannot prove cause and effect, while noting that the result is unsurprising given what is known about the biological effects of polluted air. Breathing polluted air can trigger inflammation, damage blood vessels and affect breathing, all of which could plausibly impair endurance performance. He also highlighted a positive trend: levels of nitrogen dioxide and PM2.5 on marathon day in London appear to have fallen substantially since the 2010 event, news he described as welcome for heart health, and he emphasised that exercise itself remains highly beneficial, capable of reducing the risk of heart and circulatory diseases by up to 35 per cent. The findings, he stressed, should not put people off running.

From a practical standpoint, the Leicester researchers argue that air quality and event-related traffic policies should now be considered alongside temperature and humidity when cities plan urban endurance events and when runners are advised about race preparation. Large marathons already close roads and reroute traffic; the new evidence suggests such measures may do more than manage congestion, potentially influencing the times recorded by hundreds of thousands of amateur participants. Race organisers might also weigh start times, course design and real-time air quality forecasts when scheduling and managing mass-participation events in dense urban environments.

The implications extend past the marathon finish line to anyone exercising outdoors in a city, from commuters cycling to work to children playing sport in traffic-exposed neighbourhoods. Recognising this broader relevance, researchers at the University of Leicester are developing the P-STEP app, the Personalised Space Technology Exercise Platform, with support from the European Space Agency. The app uses real-time, location-specific air quality information to help people decide when and where to exercise outdoors while minimising their exposure to pollution. Work of this kind sits within the British Heart Foundation Leicester Centre of Research Excellence, led by Director Professor André Ng, which unites discovery science, clinical intervention and population health research, and within the NIHR Biomedical Research Centre Leicester, hosted by the University Hospitals of Leicester NHS Trust in partnership with the University of Leicester, Loughborough University and University Hospitals of Northamptonshire NHS Group. Together, the study and the tools emerging from it point toward a future in which air quality data becomes a routine part of athletic planning, much as weather forecasts already are, and in which the invisible chemistry of city air is recognised as a genuine factor in human performance.

Subject of Research: The association between race-day air pollution exposure and marathon running performance across the six World Marathon Majors

Article Title: Higher pollution levels linked to slower marathon times across six world marathon majors

Article References: Higher pollution levels linked to slower marathon times across six world marathon majors. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: air pollution, nitrogen dioxide, PM2.5, marathon, World Marathon Majors, exercise performance, University of Leicester, recreational runners, public health, urban air quality, cardiovascular health, endurance sport